AEROBIKA® OPEP Device Advantage

  • Reduces COPD readmissions by 28% in the critical 30-day period
  • Trend toward shorter length of stay
  • Reduced use of oral corticosteroids and antibiotic treatments
  • Improves lung function and ventilation in COPD
  • Reduces post-operative readmissions by 39% in the critical 30-day period
  • Use of the device resulted in shorter length of stay and significantly lower costs
  • Cost effective addition to standard of care

Monaghan Medical Corporation (MMC), headquartered in Plattsburgh, New York, offers leading aerosol drug delivery devices and respiratory management products including the AeroEclipse® BAN, AeroChamber® Brand of VHC and the Aerobika® OPEP device exclusively in the United States. MMC focuses on developing cost-efficient, outcome-based solutions for its customers.

Improved quality of life
by design.